Watson Pharmaceuticals wins FDA approval for generic contraception drug
WPI | Quote | Chart | News | PowerRating -- Watson Pharmaceuticals, a specialty pharmaceutical company, has reported that its subsidiary, Watson Laboratories, has received approval from the FDA on its abbreviated new drug application for levonorgestrel tablets, 0.75mg for over-the-counter use in women ages 17 and above, as well as for prescription use in women under the age of 17.
Levonorgestrel tablets, 0.75mg is the generic equivalent to Duramed Pharmaceuticals's Plan B (Rx/OTC), which is indicated for the prevention of pregnancy following unprotected intercourse or contraceptive failure.
Watson will market the product under the trade name Next Choice and plans to launch the product shortly.
On June 24, 2009, Watson received FDA approval of Next Choice tablets, 0.75mg for prescription use. Following this approval, Next Choice is now labeled for both prescription and over-the-counter use.
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon
For full details on (DRMD) DRMD. (DRMD) has Short Term PowerRatings at TradingMarkets. Details on (DRMD) Short Term PowerRatings is available at This Link.
For full details on Watson Pharmaceuticals (WPI) WPI. Watson Pharmaceuticals (WPI) has Short Term PowerRatings at TradingMarkets. Details on Watson Pharmaceuticals (WPI) Short Term PowerRatings is available at This Link.
- Watson to Present at Barclay's 2010 Global Healthcare Conference - 03/16/10
- Watson Pharmaceuticals Inc awarded FDA approval for generic Cardizem LA - 03/16/10
- Watson Pharma Climbing After Hours on Generic Hypertension Drug Approval (WPI) - 03/15/10
- Watson Receives FDA Approval for Generic Cardizem(R) LA - 03/15/10
- Watson Pharmaceuticals wins FDA approval for prostate cancer drug - 03/12/10
- More News >>


